In November 2024, risk assets rebounded, with positive returns across various hedge fund strategies, particularly in Equity Hedged and Relative Value sectors. Macro and discretionary trading strategies also performed well, driven by favorable positions in rates and commodities, despite some mixed results in energy and metals. Overall, the market showed a constructive outlook following the US election, with significant performance dispersion among managers.
In November 2024, risk assets rebounded, with positive returns across various hedge fund strategies, particularly in Equity Hedged and Relative Value sectors. Macro and discretionary trading strategies also performed well, driven by favorable positions in rates and commodities, despite some mixed results in energy and metals. Overall, the market showed a constructive outlook following the US election, with significant performance dispersion among managers.
Markets experienced turmoil following the Federal Reserve's indication of fewer rate cuts in 2025, strengthening the dollar and prompting global central banks to reconsider their policies. While the S&P 500 and Nasdaq fell slightly, the Dow broke a 10-day losing streak, suggesting mixed investor sentiment amid heightened volatility. The upcoming U.S. personal consumption expenditures price index is expected to significantly influence market reactions.
Asian shares fell to a three-month low as investors awaited crucial U.S. inflation data, with the dollar reaching a two-year peak. The Bank of Japan's dovish stance and steady lending rates contributed to the yen's decline, while U.S. Treasury yields surged, reflecting market concerns over economic policy and geopolitical uncertainty.
The SMI is lower in pre-market trading as US stock markets close little changed following an interest rate shock, with Micron weighing on the Nasdaq. The Chinese central bank maintained key interest rates amid economic challenges, while the Shanghai stock exchange rose 0.5%. Geopolitical uncertainties and policy shocks are expected to influence markets significantly in 2025, as highlighted by TD Securities' James Rossiter. The Chinese economy faces a real estate crisis, compounded by potential tariffs from US President-elect Donald Trump.
Asian shares showed mixed results as markets awaited U.S. personal spending data. Japan's core inflation rose to 2.7%, prompting a stronger dollar against the yen. Meanwhile, U.S. markets faced volatility, with the S&P 500 still on track for a strong year despite recent fluctuations.
Asian shares showed mixed results as markets awaited U.S. personal spending data. Japan's core inflation rose to 2.7% year-on-year, prompting a stronger dollar against the yen. Meanwhile, U.S. Treasury yields fluctuated amid mixed economic reports, with the S&P 500 still on track for a strong year despite recent market struggles.
U.S. markets are set to open lower as a potential government shutdown looms, following the House's rejection of President-elect Trump's funding plan. Futures for the S&P 500 and Dow Jones fell, while FedEx shares surged 9% after exceeding profit expectations. In Europe, major indices declined, and Japan's inflation data exceeded forecasts, impacting the yen's value.
Asian shares showed mixed results as markets awaited U.S. personal spending data. Japan's core inflation rose to 2.7% year-on-year, prompting the dollar to strengthen against the yen. Meanwhile, U.S. Treasury yields fluctuated amid mixed economic reports, with the S&P 500 still on track for a strong year despite recent market struggles.
Xcovery Holdings' ensartinib, branded as Ensacove, has received FDA approval as a first-line treatment for ALK-positive non-small cell lung cancer, marking a significant milestone as the first innovative targeted lung cancer drug from a Chinese company to enter the U.S. market. While it shows a 44% reduction in progression or death compared to Pfizer's Xalkori, it faces stiff competition from established ALK inhibitors like Roche's Alecensa, which has demonstrated superior efficacy in previous studies. Despite its potential, Ensacove's market entry comes amid a landscape dominated by major pharmaceutical players.
Seems like the connection with the server has been lost. It can be due to poor or broken network. Please hang on while we're trying to reconnect...
Oh snap! Failed to reconnect with the server. This is typically caused by a longer network outage, or if the server has been taken down. You can try to reconnect, but if that does not work, you need to reload the page.
Oh man! The server rejected the attempt to reconnect. The only option now is to reload the page, but be prepared that it won't work, since this is typically caused by a failure on the server.
